scope

Promising finding for people with Type 2 diabetes and kidney disease

For nearly two decades, doctors have relied on one treatment to try to avert kidney failure in patients with Type 2 diabetes and kidney disease. That's why it's encouraging to see that new results from a large, multi-center clinical trial promise to improve on that treatment. The CREDENCE trial found that the drug canagliflozin, used along with current best available care, lowers the risk of kidney failure by a third for patients with...

scope

Type 1 diabetes: Developing an early warning system

Type 1 diabetes starts out as a sneak attack. For unknown reasons, the immune system makes antibodies against insulin and other proteins in the insulin-producing islet cells in the pancreas, targeting these healthy cells for destruction. Clinical trials have suggested that, if the attack is stopped early with immune-modulating therapies, full-blown type 1 diabetes might be prevented. But there's been a big hurdle in getting this...